Continuous Intravenous Epoprostenol for Pulmonary Arterial Hypertension: Highlighting Practical Issues, Special Considerations

Advances in Pulmonary Hypertension
doi 10.21693/1933-088x-1.3.4
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Pulmonary Hypertension Association

Related search

Continuous Intravenous Epoprostenol for Chronic Thromboembolic Pulmonary Hypertension

European Respiratory Journal
MedicinePulmonaryRespiratory Medicine
2004English

Transition of Stable Pediatric Patients With Pulmonary Arterial Hypertension From Intravenous Epoprostenol to Intravenous Treprostinil

American Journal of Cardiology
Cardiovascular MedicineCardiology
2007English

Epoprostenol Treatment for Idiopathic Pulmonary Arterial Hypertension in Pregnancy

Journal of Perinatology
GynecologyChild HealthPediatricsPerinatologyObstetrics
2010English

Pulmonary Arterial Hypertension: Diagnostic Considerations

Advances in Pulmonary Hypertension
2004English

Rapid Initiation of Intravenous Epoprostenol Infusion Is the Favored Option in Patients With Advanced Pulmonary Arterial Hypertension

Journal of Cardiac Failure
Cardiovascular MedicineCardiology
2014English

Withdrawal of Long-Term Epoprostenol Therapy in Pulmonary Arterial Hypertension (PAH)

Pulmonary Circulation
PulmonaryRespiratory Medicine
2017English

Stability and Preservation of a New Formulation of Epoprostenol Sodium for Treatment of Pulmonary Arterial Hypertension

Drug Design, Development and Therapy
Drug DiscoveryPharmacologyPharmaceutical Science
2012English

Evaluation of a New Formulation of Epoprostenol Sodium in Japanese Patients With Pulmonary Arterial Hypertension (EPITOME4)

Advances in Therapy
MedicinePharmacology
2013English

Pulmonary Arterial Hypertension

Current Problems in Cardiology
MedicineCardiovascular MedicineCardiology
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy